Assessing the Ability of the T-SPOT®.TB Test (IQ)

Oxford Immunotec

Status: Completed

Conditions: Tuberculosis (TB)

Study type: Observational

Funder types: Industry

Identifiers

NCT03929705

AF SA 148

Details and patient eligibility

About

The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA.

Full description

The target number of subjects is 100 active TB and 100 active TB excluded . This study will enroll up to 680 subjects (based on previous enrolment rates of approximately 300-350 subjects enrolled for 50 active TB and 50 active TB excluded).

Study Duration: 6 months

All subjects enrolled in this study will be men or women, aged 18 years or older.

Enrollment: 676 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Cohort 1a and 1b

• • Must be at least 18 years of age

  • Must be able to provide informed consent
  • Must be able to provide a minimum of 10 mL of whole blood at each visit (16mL for immunocompromised i.e. HIV+)
  • Must be T-SPOT.TB positive
  • First visit suspect TB subjects with no prior history of TB diagnosis Inclusion Criteria: Cohort 2a and 2b
  • Must be at least 18 years of age
  • Must be able to provide informed consent
  • Must be able to provide a minimum of 10 mL of whole blood at each visit (16mL for immunocompromised i.e. HIV+)
  • Must be T-SPOT.TB positive
  • No prior history of TB diagnosis

Exclusion Criteria: Cohort 1a and 1b

• • Negative in the T-SPOT.TB test

  • Previous or pre-existing confirmed TB diagnosis
  • On anti-TB treatment for more than 1 week*
  • Not meeting inclusion criteria Exclusion Criteria: Cohort 2a and 2b
  • Negative T-SPOT.TB test
  • Previous or pre-existing confirmed TB diagnosis
  • On anti-TB treatment
  • Symptoms of active TB
  • Not meeting inclusion criteria

Trial design

676 participants in 2 patient groups

Test Arm 1- T-SPOT.TB assay

Description:

T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.

Test Arm 2 -QuantiFERON-TB Gold Plus assay

Description:

QuantiFERON-TB Gold Plus, for each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.